DURECT Corp
NASDAQ:DRRX

Watchlist Manager
DURECT Corp Logo
DURECT Corp
NASDAQ:DRRX
Watchlist
Price: 1.26 USD -2.33% Market Closed
Market Cap: 39.1m USD
Have any thoughts about
DURECT Corp?
Write Note

Intrinsic Value

DRRX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one DRRX stock under the Base Case scenario is 2.4 USD. Compared to the current market price of 1.26 USD, DURECT Corp is Undervalued by 47%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

DRRX Intrinsic Value
2.4 USD
Undervaluation 47%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
DURECT Corp

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for DRRX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about DRRX?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about DURECT Corp

Provide an overview of the primary business activities
of DURECT Corp.

What unique competitive advantages
does DURECT Corp hold over its rivals?

What risks and challenges
does DURECT Corp face in the near future?

Has there been any significant insider trading activity
in DURECT Corp recently?

Summarize the latest earnings call
of DURECT Corp.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for DURECT Corp.

Provide P/S
for DURECT Corp.

Provide P/E
for DURECT Corp.

Provide P/OCF
for DURECT Corp.

Provide P/FCFE
for DURECT Corp.

Provide P/B
for DURECT Corp.

Provide EV/S
for DURECT Corp.

Provide EV/GP
for DURECT Corp.

Provide EV/EBITDA
for DURECT Corp.

Provide EV/EBIT
for DURECT Corp.

Provide EV/OCF
for DURECT Corp.

Provide EV/FCFF
for DURECT Corp.

Provide EV/IC
for DURECT Corp.

Show me price targets
for DURECT Corp made by professional analysts.

What are the Revenue projections
for DURECT Corp?

How accurate were the past Revenue estimates
for DURECT Corp?

What are the Net Income projections
for DURECT Corp?

How accurate were the past Net Income estimates
for DURECT Corp?

What are the EPS projections
for DURECT Corp?

How accurate were the past EPS estimates
for DURECT Corp?

What are the EBIT projections
for DURECT Corp?

How accurate were the past EBIT estimates
for DURECT Corp?

Compare the revenue forecasts
for DURECT Corp with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of DURECT Corp and its key competitors using the latest financial data.

Compare historical revenue growth rates
of DURECT Corp against its competitors.

Analyze the profit margins
(gross, operating, and net) of DURECT Corp compared to its peers.

Compare the P/E ratios
of DURECT Corp against its peers.

Discuss the investment returns and shareholder value creation
comparing DURECT Corp with its peers.

Analyze the financial leverage
of DURECT Corp compared to its main competitors.

Show all profitability ratios
for DURECT Corp.

Provide ROE
for DURECT Corp.

Provide ROA
for DURECT Corp.

Provide ROIC
for DURECT Corp.

Provide ROCE
for DURECT Corp.

Provide Gross Margin
for DURECT Corp.

Provide Operating Margin
for DURECT Corp.

Provide Net Margin
for DURECT Corp.

Provide FCF Margin
for DURECT Corp.

Show all solvency ratios
for DURECT Corp.

Provide D/E Ratio
for DURECT Corp.

Provide D/A Ratio
for DURECT Corp.

Provide Interest Coverage Ratio
for DURECT Corp.

Provide Altman Z-Score Ratio
for DURECT Corp.

Provide Quick Ratio
for DURECT Corp.

Provide Current Ratio
for DURECT Corp.

Provide Cash Ratio
for DURECT Corp.

What is the historical Revenue growth
over the last 5 years for DURECT Corp?

What is the historical Net Income growth
over the last 5 years for DURECT Corp?

What is the current Free Cash Flow
of DURECT Corp?

Discuss the annual earnings per share (EPS)
trend over the past five years for DURECT Corp.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
DURECT Corp

Current Assets 20m
Cash & Short-Term Investments 15.6m
Receivables 1m
Other Current Assets 3.3m
Non-Current Assets 9.9m
PP&E 3.5m
Intangibles 6.2m
Other Non-Current Assets 278k
Current Liabilities 21.9m
Accounts Payable 394k
Accrued Liabilities 5.9m
Other Current Liabilities 15.6m
Non-Current Liabilities 2.9m
Other Non-Current Liabilities 2.9m
Efficiency

Earnings Waterfall
DURECT Corp

Revenue
8.4m USD
Cost of Revenue
-1.6m USD
Gross Profit
6.8m USD
Operating Expenses
-31.7m USD
Operating Income
-24.9m USD
Other Expenses
9.1m USD
Net Income
-15.8m USD

Free Cash Flow Analysis
DURECT Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

DURECT reported a slight increase in Q2 2024 revenues to $2.2 million. Notably, R&D expenses significantly decreased by $5.7 million, primarily due to lower clinical trial costs. Operating expenses are expected to remain steady at $3.5-$4 million per quarter. The company is preparing for a Phase III trial of larsucosterol for alcohol-associated hepatitis, aiming to start by year-end and report data by the second half of 2026. Larsucosterol showed promising Phase IIb results, reducing US patient mortality by nearly 60%, and received Breakthrough Therapy designation from the FDA.

What is Earnings Call?
Fundamental Scores

DRRX Profitability Score
Profitability Due Diligence

DURECT Corp's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
ROIC is Increasing
Negative 3-Years Revenue Growth
24/100
Profitability
Score

DURECT Corp's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

DRRX Solvency Score
Solvency Due Diligence

DURECT Corp's solvency score is 47/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
47/100
Solvency
Score

DURECT Corp's solvency score is 47/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

DRRX Price Targets Summary
DURECT Corp

Wall Street analysts forecast DRRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DRRX is 6.89 USD with a low forecast of 5.05 USD and a high forecast of 8.93 USD.

Lowest
Price Target
5.05 USD
301% Upside
Average
Price Target
6.89 USD
446% Upside
Highest
Price Target
8.93 USD
608% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for DRRX?

Click here to dive deeper.

Dividends

DURECT Corp
does not pay dividends
Shareholder Yield

Current shareholder yield for DRRX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

DRRX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

DURECT Corp Logo
DURECT Corp

Country

United States of America

Industry

Pharmaceuticals

Market Cap

39.1m USD

Dividend Yield

0%

Description

DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. The company is headquartered in Cupertino, California and currently employs 79 full-time employees. The company went IPO on 2000-09-28. The firm's product candidates include DUR-928 oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. The Company’s other commercial product candidates include POSIMIR, PERSERIS and Methydur Sustained Release Capsules. The firm is conducting a Phase IIb study (AHFIRM) of larsucosterol (DUR-928) in subjects with severe alcohol-associated hepatitis (Alcoholic Hepatitis (AH) to evaluate the safety and efficacy of larsucosterol treatment. Larsucosterol (DUR-928) is lead product candidate, an endogenous sulfated oxysterol and an epigenetic regulator. The firm focuses on drug delivery technology around its SABER and CLOUD Bioerodible Injectable Depot Systems. SABER uses a high viscosity base component, such as sucrose acetate isobutyrate (SAIB), to provide controlled release of a drug.

Contact

CALIFORNIA
Cupertino
10260 Bubb Rd
+14087771417.0
www.durect.com

IPO

2000-09-28

Employees

79

Officers

See Also

Discover More
What is the Intrinsic Value of one DRRX stock?

The intrinsic value of one DRRX stock under the Base Case scenario is 2.4 USD.

Is DRRX stock undervalued or overvalued?

Compared to the current market price of 1.26 USD, DURECT Corp is Undervalued by 47%.

Back to Top